A61K 2239/10
Characterized by the structure of the chimeric antigen receptor [car]
Official title: characterized by the structure of the chimeric antigen receptor [CAR]
A61K2239/10 (Characterized by the structure of the chimeric antigen receptor [car]) appears on 282 US grants and 1,403 published applications in this corpus.
Search patents in A61K- Granted patents
- 282
- Published applications
- 1,403
- Assignees
- 570
- Inventors
- 3,201
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 1 | 3 |
| 2013 | 2 | 1 |
| 2014 | 0 | 7 |
| 2015 | 1 | 5 |
| 2016 | 0 | 12 |
| 2017 | 8 | 24 |
| 2018 | 6 | 38 |
| 2019 | 11 | 34 |
| 2020 | 20 | 44 |
| 2021 | 17 | 63 |
| 2022 | 19 | 79 |
| 2023 | 32 | 164 |
| 2024 | 48 | 372 |
| 2025 | 65 | 326 |
| 2026 | 50 | 224 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Modified cell line and method for expansion of NK cell123US 7,435,596 B2St. Jude Children?S Research Hospital · 2008
- Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy108US 9,745,368 B2Novartis AG · 2017
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Expansion of NK cells and therapeutic uses thereof72US 8,026,097 B2St. Jude Children?S Research Hospital · 2011